146 related articles for article (PubMed ID: 16773073)
1. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases.
Stea B; Shaw E; Pintér T; Hackman J; Craig M; May J; Steffen RP; Suh JH
Br J Cancer; 2006 Jun; 94(12):1777-84. PubMed ID: 16773073
[TBL] [Abstract][Full Text] [Related]
2. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
3. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.
Suh JH; Stea B; Nabid A; Kresl JJ; Fortin A; Mercier JP; Senzer N; Chang EL; Boyd AP; Cagnoni PJ; Shaw E
J Clin Oncol; 2006 Jan; 24(1):106-14. PubMed ID: 16314619
[TBL] [Abstract][Full Text] [Related]
4. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases.
Scott C; Suh J; Stea B; Nabid A; Hackman J
Am J Clin Oncol; 2007 Dec; 30(6):580-7. PubMed ID: 18091051
[TBL] [Abstract][Full Text] [Related]
5. Role of efaproxiral in metastatic brain tumors.
Engel RH; Kaklamani VG
Expert Rev Anticancer Ther; 2006 Apr; 6(4):477-85. PubMed ID: 16613536
[TBL] [Abstract][Full Text] [Related]
6. Efaproxiral: a novel radiation sensitiser.
Suh JH
Expert Opin Investig Drugs; 2004 May; 13(5):543-50. PubMed ID: 15155129
[TBL] [Abstract][Full Text] [Related]
7. Efaproxiral: a radiation enhancer used in brain metastases from breast cancer.
Charpentier MM
Ann Pharmacother; 2005 Dec; 39(12):2038-45. PubMed ID: 16249270
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics.
Kavanagh BD; Khandelwal SR; Schmidt-Ullrich RK; Roberts JD; Shaw EG; Pearlman AD; Venitz J; Dusenbery KE; Abraham DJ; Gerber MJ
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1133-9. PubMed ID: 11240256
[TBL] [Abstract][Full Text] [Related]
9. Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
Choy H; Nabid A; Stea B; Scott C; Roa W; Kleinberg L; Ayoub J; Smith C; Souhami L; Hamburg S; Spanos W; Kreisman H; Boyd AP; Cagnoni PJ; Curran WJ
J Clin Oncol; 2005 Sep; 23(25):5918-28. PubMed ID: 16135463
[TBL] [Abstract][Full Text] [Related]
10. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.
Kleinberg L; Grossman SA; Carson K; Lesser G; O'Neill A; Pearlman J; Phillips P; Herman T; Gerber M
J Clin Oncol; 2002 Jul; 20(14):3149-55. PubMed ID: 12118029
[TBL] [Abstract][Full Text] [Related]
11. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database.
Shaw E; Scott C; Suh J; Kadish S; Stea B; Hackman J; Pearlman A; Murray K; Gaspar L; Mehta M; Curran W; Gerber M
J Clin Oncol; 2003 Jun; 21(12):2364-71. PubMed ID: 12805339
[TBL] [Abstract][Full Text] [Related]
12. Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: Determinants of response and its prognostic value for subsequent survival.
Stea B; Suh JH; Boyd AP; Cagnoni PJ; Shaw E;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1023-30. PubMed ID: 16446056
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme.
Kleinberg L; Grossman SA; Piantadosi S; Pearlman J; Engelhard H; Lesser G; Ruffer J; Gerber M
J Clin Oncol; 1999 Aug; 17(8):2593-603. PubMed ID: 10561327
[TBL] [Abstract][Full Text] [Related]
14. The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice.
Hou H; Khan N; Grinberg OY; Yu H; Grinberg SA; Lu S; Demidenko E; Steffen RP; Swartz HM
Radiat Res; 2007 Aug; 168(2):218-25. PubMed ID: 17638413
[TBL] [Abstract][Full Text] [Related]
15. Detection of efaproxiral (RSR13) and its metabolites in equine by liquid chromatography tandem mass spectrometry.
Yi R; Sandhu J; Zhao S; Lam G; Loganathan D; Morrissey B
J Mass Spectrom; 2014 Jan; 49(1):57-67. PubMed ID: 24446264
[TBL] [Abstract][Full Text] [Related]
16. Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study.
Hou H; Khan N; O'Hara JA; Grinberg OY; Dunn JF; Abajian MA; Wilmot CM; Demidenko E; Lu S; Steffen RP; Swartz HM
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1503-9. PubMed ID: 15817356
[TBL] [Abstract][Full Text] [Related]
17. RSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSAII and SCCVII tumours in C3H mice.
Khandelwal SR; Kavanagh BD; Lin PS; Truong QT; Lu J; Abraham DJ; Schmidt-Ullrich RK
Br J Cancer; 1999 Feb; 79(5-6):814-20. PubMed ID: 10070874
[TBL] [Abstract][Full Text] [Related]
18. Allosteric modification of hemoglobin by RSR13 as a therapeutic strategy.
Steffen RP; Liard JF; Gerber MJ; Hoffman SJ
Adv Exp Med Biol; 2003; 530():249-59. PubMed ID: 14562722
[TBL] [Abstract][Full Text] [Related]
19. Efaproxiral (RSR13) plus oxygen breathing increases the therapeutic ratio of carboplatin in EMT6 mouse mammary tumors.
Donnelly ET; Liu Y; Rockwell S
Exp Biol Med (Maywood); 2006 Mar; 231(3):317-21. PubMed ID: 16514179
[TBL] [Abstract][Full Text] [Related]
20. Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study.
Mehta MP; Wang D; Wang F; Kleinberg L; Brade A; Robins HI; Turaka A; Leahy T; Medina D; Xiong H; Mostafa NM; Dunbar M; Zhu M; Qian J; Holen K; Giranda V; Curran WJ
J Neurooncol; 2015 Apr; 122(2):409-17. PubMed ID: 25682091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
